CORAL LABORATORIES
|
CORAL LABORATORIES Last 5 Year Financial Ratios History
[Standalone]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 18.04 | 25.32 | 37.94 | 19.96 | 28.60 |
| CEPS(Rs) | 24.14 | 30.89 | 43.49 | 25.58 | 33.92 |
| DPS(Rs) | - | - | - | - | 2.00 |
| Book NAV/Share(Rs) | 433.29 | 436.81 | 382.48 | 323.77 | 318.45 |
| Tax Rate(%) | 21.65 | 23.70 | 23.04 | 21.79 | 34.11 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 4.88 | 10.86 | 16.41 | 7.68 | 13.64 |
| EBIT Margin(%) | 10.96 | 15.87 | 18.28 | 13.19 | 17.21 |
| Pre Tax Margin(%) | 10.53 | 15.68 | 18.24 | 12.92 | 17.02 |
| PAT Margin (%) | 8.25 | 11.96 | 14.04 | 10.10 | 11.22 |
| Cash Profit Margin (%) | 11.04 | 14.60 | 16.09 | 12.95 | 13.31 |
| Performance Ratios | |||||
| ROA(%) | 3.54 | 5.06 | 8.69 | 5.09 | 7.40 |
| ROE(%) | 4.15 | 6.18 | 10.74 | 6.22 | 8.88 |
| ROCE(%) | 5.41 | 7.87 | 13.35 | 7.86 | 13.44 |
| Asset Turnover(x) | 0.43 | 0.42 | 0.62 | 0.50 | 0.66 |
| Sales/Fixed Asset(x) | 1.64 | 1.74 | 2.36 | 1.77 | 2.40 |
| Working Capital/Sales(x) | 0.70 | 0.72 | 0.96 | 1.00 | 1.39 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.61 | 0.58 | 0.42 | 0.56 | 0.42 |
| Receivable days | 143.76 | 186.51 | 139.03 | 167.38 | 124.10 |
| Inventory Days | 72.11 | 96.64 | 77.43 | 91.72 | 67.57 |
| Payable days | 75.80 | 167.30 | 164.79 | 181.18 | 144.27 |
| Valuation Parameters | |||||
| PER(x) | 12.69 | 10.08 | 8.49 | 4.91 | 11.06 |
| PCE(x) | 9.48 | 8.26 | 7.41 | 3.83 | 9.32 |
| Price/Book(x) | 0.53 | 0.58 | 0.84 | 0.30 | 0.99 |
| Yield(%) | - | - | - | - | 0.63 |
| EV/Net Sales(x) | 0.53 | 0.79 | 0.90 | 0.15 | 1.00 |
| EV/Core EBITDA(x) | 3.86 | 4.59 | 4.41 | 0.97 | 5.21 |
| EV/EBIT(x) | 4.83 | 4.98 | 4.90 | 1.17 | 5.84 |
| EV/CE(x) | 0.24 | 0.31 | 0.52 | 0.08 | 0.67 |
| M Cap / Sales | 1.05 | 1.21 | 1.19 | 0.50 | 1.24 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 3.32 | -21.70 | 36.82 | -22.51 | -1.51 |
| Core EBITDA Growth(%) | -17.82 | -33.60 | 73.39 | -35.62 | -11.29 |
| EBIT Growth(%) | -28.61 | -32.05 | 89.67 | -40.61 | -14.12 |
| PAT Growth(%) | -28.75 | -33.26 | 90.10 | -30.21 | -17.91 |
| EPS Growth(%) | -28.75 | -33.26 | 90.10 | -30.21 | -17.91 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | 0.04 | 0.05 | 0.05 | 0.01 |
| Current Ratio(x) | 10.42 | 5.13 | 4.67 | 3.82 | 4.64 |
| Quick Ratio(x) | 9.36 | 4.41 | 3.88 | 3.05 | 3.74 |
| Interest Cover(x) | 25.30 | 85.02 | 415.41 | 48.68 | 93.80 |
| Total Debt/Mcap(x) | - | 0.07 | 0.05 | 0.17 | 0.01 |
Compare Financial Ratios of peers of CORAL LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CORAL LABORATORIES | ₹133.9 Cr | 0.7% | 3.2% | 67% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹364,015.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
| CIPLA | ₹108,809.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,408.7 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹98,684.0 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹94,213.7 Cr | 5% | 10.4% | 109.1% | Stock Analytics | |
CORAL LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CORAL LABORATORIES | 0.7% |
3.2% |
67% |
| SENSEX | -2.9% |
-0.4% |
20% |
You may also like the below Video Courses
